Endo Against Lipid Lowering Therapies Hyperandrogenism Infertility Pcos

Avoid lipid-lowering therapies to treat hyperandrogenism or infertility in polycystic ovary syndrome

STEP 1 — Gather Information

• Confirm PCOS diagnosis per Rotterdam criteria (oligo-ovulation, hyperandrogenism, polycystic ovaries).
• Assess presence of hyperandrogenism (e.g., hirsutism, acne, elevated androgens) or infertility concerns.
• Review menstrual history, fertility goals, and pregnancy status.
• Obtain baseline lipid panel to evaluate CVD risk. Action: Proceed to step 2 if hyperandrogenism or infertility is the primary treatment target.

STEP 2 — Rule In / Rule Out

• If the clinical goal is to treat hyperandrogenism or infertility → Rule in for avoiding lipid-lowering therapies for these indications.
• Else if the goal is CVD risk reduction → Rule out; proceed to assess CVD risk. Decision: If ruling in, skip lipid-lowering therapy for hyperandrogenism/infertility and go to Step 4; if ruling out, go to Step 3.

STEP 3 — Classify or Stratify

• Calculate 10-year ASCVD risk using Pooled Cohort Equations.
• Consider risk-enhancing factors (e.g., family history, LDL-C ≥160 mg/dL, metabolic syndrome).
• Classify risk as low (<5%), borderline (5-7.4%), intermediate (7.5-19.9%), or high (≥20%). Action: If ASCVD risk indicates statin benefit (per guideline thresholds), consider lipid-lowering therapy for CVD prevention; otherwise, advise lifestyle measures only.

STEP 4 — Decide

• If hyperandrogenism/infertility was the target: do not prescribe lipid-lowering therapy; reinforce lifestyle modifications (weight management, exercise, OCPs if appropriate) for hyperandrogenism/infertility.
• If CVD risk indicates need: prescribe appropriate lipid-lowering therapy (e.g., statin) for ASCVD prevention, ensuring contraception if of reproductive potential. Action: Implement decision and document rationale.

Clinical Guardrails / Mimics / Pitfalls

• Do not use statins or other lipid-lowering agents solely to improve androgen levels or fertility outcomes in PCOS.
• Avoid statins in pregnancy or when attempting conception due to teratogenic risk.
• Recognize that lifestyle change remains first-line for hyperandrogenism and infertility in PCOS.
• Beware of mistaking elevated LDL-C in PCOS as requiring statin therapy for reproductive symptoms.
• Monitor for muscle symptoms, hepatic enzymes, and pregnancy status if statins are used for CVD prevention.

Concrete Clinical Example

A 28-year-old woman with PCOS presents for infertility counseling; she has hirsutism and elevated testosterone. She requests a statin to lower androgens. After confirming PCOS and infertility as the goal, lipid-lowering therapy is discouraged; instead, clomiphene citrate and lifestyle modification are initiated for ovulation induction.

Source: Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, https://doi.org/10.1210/clinem/dgaa674